{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:54Z","timestamp":1740106914790,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K11537"],"award-info":[{"award-number":["JP24K11537"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-05934-2","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T13:14:02Z","timestamp":1724332442000},"page":"5639-5649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-7220","authenticated-orcid":false,"given":"Yutaka","family":"Shimazu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhito","family":"Takakuwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Onda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Fuchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"5934_CR1","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, Sonneveld P, Leung N et al (2016) International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34. https:\/\/doi.org\/10.1200\/JCO.2015.65.0044","DOI":"10.1200\/JCO.2015.65.0044"},{"key":"5934_CR2","doi-asserted-by":"publisher","unstructured":"Eleutherakis-Papaiakovou V, Bamias A, Gika D et al (2007) Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 48. https:\/\/doi.org\/10.1080\/10428190601126602","DOI":"10.1080\/10428190601126602"},{"key":"5934_CR3","doi-asserted-by":"publisher","unstructured":"Yadav P, Cook M, Cockwell P (2015) Current trends of renal impairment in multiple myeloma. https:\/\/doi.org\/10.1159\/000442511. Kidney Diseases 1:","DOI":"10.1159\/000442511"},{"key":"5934_CR4","doi-asserted-by":"crossref","unstructured":"Fotiou D, Dimopoulos MA, Kastritis E (2016) Managing renal complications in multiple myeloma. Expert Rev Hematol 9","DOI":"10.1080\/17474086.2016.1210003"},{"key":"5934_CR5","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1093\/NDT\/GFS449","volume":"27","author":"A Davenport","year":"2012","unstructured":"Davenport A, Merlini G (2012) Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. Nephrol Dial Transpl 27:3713\u20133718. https:\/\/doi.org\/10.1093\/NDT\/GFS449","journal-title":"Nephrol Dial Transpl"},{"key":"5934_CR6","doi-asserted-by":"publisher","unstructured":"Hutchison CA, Cockwell P, Stringer S et al (2011) Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 22. https:\/\/doi.org\/10.1681\/ASN.2010080857","DOI":"10.1681\/ASN.2010080857"},{"key":"5934_CR7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375:1319\u20131331. https:\/\/doi.org\/10.1056\/NEJMoa1607751","journal-title":"N Engl J Med"},{"key":"5934_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A et al (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373:621\u2013631","journal-title":"N Engl J Med"},{"key":"5934_CR9","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV et al (2019) Isatuximab plus Pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394:2096\u20132107. https:\/\/doi.org\/10.1016\/S0140-6736(19)32556-5","journal-title":"Lancet"},{"key":"5934_CR10","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1111\/cas.15163","volume":"112","author":"Y Shimazu","year":"2021","unstructured":"Shimazu Y, Mizuno S, Fuchida S, ichi et al (2021) Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine. Cancer Sci 112:5034\u20135045. https:\/\/doi.org\/10.1111\/cas.15163","journal-title":"Cancer Sci"},{"key":"5934_CR11","doi-asserted-by":"publisher","unstructured":"Iida S, Ishida T, Murakami H et al (2019) JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). Int J Hematol 109. https:\/\/doi.org\/10.1007\/s12185-019-02636-8","DOI":"10.1007\/s12185-019-02636-8"},{"key":"5934_CR12","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S et al (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127:2955\u20132962","journal-title":"Blood"},{"key":"5934_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transpl 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transpl"},{"key":"5934_CR14","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A et al (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28:4976\u20134984. https:\/\/doi.org\/10.1200\/JCO.2010.30.8791","journal-title":"J Clin Oncol"},{"key":"5934_CR15","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/nejmoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T et al (2019) Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380:2104\u20132115. https:\/\/doi.org\/10.1056\/nejmoa1817249","journal-title":"N Engl J Med"},{"key":"5934_CR16","doi-asserted-by":"publisher","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M et al (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378. https:\/\/doi.org\/10.1056\/nejmoa1714678","DOI":"10.1056\/nejmoa1714678"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05934-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05934-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:07:15Z","timestamp":1735866435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05934-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5934"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05934-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving the patient were by the ethical standards. This study was approved by the Kyoto University Certified Review Board (approval no. R4159, approved date: September 13th, 2023) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The informed consent requirement for this retrospective study was waived because the study was conducted retrospectively and the opportunity to refuse was guaranteed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Junya Kanda has received honoraria from Janssen Pharmaceutical K.K., Megakaryon Corporation, Abbvie GK., Amgen Inc., Asahi Kasei Pharma Corporation, and Daiichi Sankyo Co. Ltd., and Grant\/Research funding from Eisai Co. and MSD K.K. Teruhito Takakuwa has received honoraria from Sanofi K.K. and Research funding from Abbvie GK., GSK, Pfizer Japan Inc., Bristol-Myers Squibb Company, Janssen Pharmaceutical K.K., and Incyte Biosciences Japan. Shin-ichi Fuchida has received honoraria from Takeda Pharmaceutical Co. Ltd., Sanofi K.K., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co. Ltd., and Bristol-Myers Squibb Company. Nobuhiko Uoshima has received honoraria from Bristol-Myers Squibb Company and Abbvie GK. Yuji Shimura has received honoraria from Bristol-Myers Squib Company. Kensuke Ohta has received honoraria from Takeda Pharmaceutical Co. Ltd., Jassen Pharmaceutical, and PharmaEssentia. Hirohiko Shibayama has received honoraria from Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Jassen Pharmaceutical, Chugai Pharmaceutical Co. Ltd., AstraZeneca, Sanofi K.K., Fujimoto, Meiji Seika Pharma, Nippon-shinyaku, Bristol-Myers Squibb Company, and Abbvie GK. Satoshi Yoshihara has received honoraria from Bristol-Myers Squibb Company, Janssen Pharmaceutical K.K., and Novartis Pharma K.K. Naoki Hosen has received honoraria from Chugai Pharmaceutical Co. Ltd., Jassen Pharmaceutical, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., and Novartis Pharma KK and Research funding from Otsuka Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., and Shionogi and Grand funding from Chugai Pharmaceutical Co. Ltd., Kyowakirin, Shionogi, Asahi Kasei Pharma Corporation, Otsuka Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Company Limited. Tomoki Ito has received honoraria from Bristol-Myers Squibb Company and Abbvie GK. Chihiro Shimazaki has received honoraria from Janssen. Itaru Matsumura has received honoraria from Chugai Pharmaceutical Co. Ltd., Novartis Pharma KK, Bristol-Myers Squibb Company, Pfizer Japan Inc., Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Abbvie GK., Takeda Pharmacuetical Company Limited., Ono Pharmaceutical Co. Ltd., SymBio Pharmaceuticals Limited, Sanofi K.K., and AstraZeneca, and Research funding from AbbVie GK., Otsuka Pharmaceutical Co. Ltd., Genmab K.K., Novartis Pharma K.K., and Incyte Japan, and Grand funding from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd., Asahi Kasei Pharma Corporation, Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd, and AbbVie GK. Junya Kuroda has received honoraria from Janssen Pharmaceutical K.K., Bristol-Myers Squibb, Sanofi K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., and Novartis Pharma K.K., and Research funding from Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd., and Sysmex and Grand funding from Kyowa Kirin Co., Chugai Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., and Shionogi & Co., Ltd. Akifumi Takaori-Kondo has received honoraria from Bristol-Myers Squibb Company, Janssen Pharmaceutical K.K., Megakaryon Corporation, AstraZeneca, Abbvie GK., and Gilead Sciences, Inc. and Research funding from Ono Pharmaceutical Co. Ltd., and DKS Co. Ltd. and Research funding from Asahi Kasei Pharma Corporation, AbbVie GK, Eisai Co., Otsuka Pharmaceutical Co., Ltd, Kyowa Kirin Co., Ltd, Shionogi & Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., and Japan Society of Hematology. Masayuki Hino has received honoraria from Novartis Pharma KK, Kyowa Kirin Co., Janssen Pharmaceutical K.K., Otsuka Pharmaceutical Co., Ltd, and Bristol-Myers Squibb, and Research funding from Fortrea Japan and Grand funding from Otsuka Pharmaceutical Co., Ltd, Kyowa Kirin Co., Chugai Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd. The other authors have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}